KR900702018A - 단백질과 핵산 - Google Patents

단백질과 핵산

Info

Publication number
KR900702018A
KR900702018A KR1019900700399A KR900700399A KR900702018A KR 900702018 A KR900702018 A KR 900702018A KR 1019900700399 A KR1019900700399 A KR 1019900700399A KR 900700399 A KR900700399 A KR 900700399A KR 900702018 A KR900702018 A KR 900702018A
Authority
KR
South Korea
Prior art keywords
analog
region
mutation
substituent
hexane
Prior art date
Application number
KR1019900700399A
Other languages
English (en)
Inventor
리차드 마크 에드워즈
케이쓰 다우슨
안쏘니 팰론
스튜워트 크래이그
Original Assignee
원본미기재
브리티쉬 바이오-테크놀로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 브리티쉬 바이오-테크놀로지 리미티드 filed Critical 원본미기재
Publication of KR900702018A publication Critical patent/KR900702018A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B4/00—Electrothermal treatment of ores or metallurgical products for obtaining metals or alloys
    • C22B4/02—Light metals
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B4/00—Electrothermal treatment of ores or metallurgical products for obtaining metals or alloys
    • C22B4/06—Alloys
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22C—ALLOYS
    • C22C1/00—Making non-ferrous alloys
    • C22C1/02—Making non-ferrous alloys by melting
    • C22C1/026—Alloys based on aluminium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Geology (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental & Geological Engineering (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

단백질과 헥산
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 t-PA의 일차 배열순서와 구역 조직을 도해식으로 나타낸 도면, 제2도는 t-PA GF구역의 묘형도, 제3도는 전형적인 압착 방법을 도해형태로 나타낸 도해도.

Claims (15)

  1. 성장 인자(GF)구역에서 최소한 하나의 치환체를 갖는 섬유소 분해적 활성을 갖는 조직 플라스미노겐 활성제(t-PA)의 유사체.
  2. 제1항에 있어서, 최소한 두개의 치환체를 갖는 t-PA 유사체.
  3. 제1항 또는 제2항에 있어서, 잔유물 63-72을 포함하는 베타-시이트에 최소한 하나의 치환체를 갖는 t-PA유사체.
  4. 제1항 또는 제2항에 있어서, Tyr67과/또는 Phe68에서 치환체를 갖는 t-PA유사체.
  5. 제1항 또는 제2항에 있어서, 지역 63-72에서 최소한의 유사체의 2차구조가 천연 t-PA와 동일함을 특징으로 하는 t-PA유사체.
  6. 제1항에 있어서, 최소한 하나의 다른 돌연변이로 이루어짐을 특징으로 하는 t-PA 유사체.
  7. 제6항에 있어서, t-PA억제물 결합을 방해하는 세린 프로타아제 구역에서 돌연변이를 가짐을 특징으로하는 t-PA유사체.
  8. 혈액의 안정성 또는 섬유소뷴해 활성도를 실제 위험하게 하지 않고 간수용기 결합이 최소한 부분적으로 감소되는 성장 인자 (GF) 구역에서 최소한 하나의 변이를 갖는 조직 플라스미노겐 활성체(t-PA)의 유사체를 코오드화 하는 핵산.
  9. 제8항에 있어서, 제2항에 언급된 t-PA 유사체를 코우드화함을 특징으로 하는 헥산.
  10. 제9항의 헥산을 압착한 세포선.
  11. 제1항에 있어서, 의약품 또는 수의약품에 사용함을 특징으로 하는 t-PA 유사체.
  12. 하나 또는 그 이상의 제1항의 t-PA 유사체와 제약학적으로 또는 수의약학 적으로 수용가능한 담체로 이루어짐을 특징으로 하는 제약학적 조성물.
  13. 제12항에 있어서, 정맥내 투여에 사용함을 특징으로 하는 조성물.
  14. 혈전 용해제의 제조에 사용하는 제1항의 t-PA 유사체의 용도.
  15. 제1항의 비독성 유효량의 t-PA 유사체를 투여함을 특징으로 하는 혈전병 치료 또는 예방 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900700399A 1988-06-24 1989-06-23 단백질과 핵산 KR900702018A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8815135,2 1988-06-24
GB888815135A GB8815135D0 (en) 1988-06-24 1988-06-24 Proteins & nucleic acids
PCT/GB1989/000705 WO1989012681A1 (en) 1988-06-24 1989-06-23 Tissue plasminogen activator analogues having improved activity

Publications (1)

Publication Number Publication Date
KR900702018A true KR900702018A (ko) 1990-12-05

Family

ID=10639339

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700399A KR900702018A (ko) 1988-06-24 1989-06-23 단백질과 핵산

Country Status (15)

Country Link
US (1) US5232847A (ko)
EP (1) EP0352904A1 (ko)
JP (1) JPH03505524A (ko)
KR (1) KR900702018A (ko)
AU (1) AU627475B2 (ko)
DK (1) DK305490A (ko)
FI (1) FI906322A0 (ko)
GB (1) GB8815135D0 (ko)
HU (1) HUT61593A (ko)
IL (1) IL90745A0 (ko)
NO (1) NO905561L (ko)
NZ (1) NZ229691A (ko)
PT (1) PT90976A (ko)
WO (1) WO1989012681A1 (ko)
ZA (1) ZA894800B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5346824A (en) * 1988-05-20 1994-09-13 Genentech, Inc. DNA encoding variants of tissue plasminogen activators and expression vectors and hosts thereof
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
JPH0595786A (ja) * 1991-10-07 1993-04-20 Green Cross Corp:The 変異ヒトプロウロキナーゼ
ATE155816T1 (de) * 1992-06-03 1997-08-15 Genentech Inc Varianten des gewebeplasminogenaktivators mit verbesserter therapeutischer wirkung
US6027888A (en) * 1996-04-05 2000-02-22 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
US6083715A (en) * 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293394B2 (en) * 1986-01-31 2003-10-29 Genetics Institute, LLC Novel thrombolytic proteins
GB8608014D0 (en) * 1986-04-02 1986-05-08 Beecham Group Plc Compounds
PT84589B (en) * 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
AU7090687A (en) * 1986-04-02 1987-10-08 Beecham Group Plc Modified tissue-type plasminogen activators
FI101306B (fi) * 1987-06-04 1998-05-29 Zymogenetics Inc Menetelmä kudostyyppisen plasminogeeniaktivaattorin analogien, joissa on muokatut kasvutekijädomeenit, valmistamiseksi
AU613942B2 (en) * 1987-06-30 1991-08-15 Genentech Inc. Improved processes for the treatment of vascular disease
EP0394261A4 (en) * 1987-07-06 1991-09-11 Genetics Institute, Inc. Novel thrombolytic proteins
US4963357A (en) * 1987-10-09 1990-10-16 Monsanto Company Tissue plasminogen activator modified by the substitution of Arg for Cys at position 73, methods and pharmaceutical compositions therefor
US5108901A (en) * 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
JPH02273179A (ja) * 1988-12-12 1990-11-07 Yamanouchi Pharmaceut Co Ltd 新規な血栓溶解蛋白質，その製造法および該蛋白質からなる医薬

Also Published As

Publication number Publication date
AU627475B2 (en) 1992-08-27
NO905561D0 (no) 1990-12-21
FI906322A0 (fi) 1990-12-20
HUT61593A (en) 1993-01-28
NZ229691A (en) 1992-03-26
HU893786D0 (en) 1991-05-28
AU3838189A (en) 1990-01-12
WO1989012681A1 (en) 1989-12-28
DK305490D0 (da) 1990-12-21
DK305490A (da) 1991-02-20
JPH03505524A (ja) 1991-12-05
NO905561L (no) 1991-02-22
GB8815135D0 (en) 1988-08-03
IL90745A0 (en) 1990-03-19
US5232847A (en) 1993-08-03
EP0352904A1 (en) 1990-01-31
ZA894800B (en) 1990-05-30
PT90976A (pt) 1989-12-29

Similar Documents

Publication Publication Date Title
DE60036017T3 (de) Verfahren zur thrombolyse durch lokale behandlung mit reversibel inaktiviertem, angesäuertem plasmin
CA1158551A (en) Plasminogen preparations
CA2025900A1 (en) Derivative of tissue-type plasminogen activator
US6964764B2 (en) Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
ATE72990T1 (de) Pharmazeutische zusammensetzung vom fluessig/gel- phasenuebergangstyp.
KR870005647A (ko) 안정화된 인체 조직 플라스미노겐 활성제 조성물
KR900702018A (ko) 단백질과 핵산
US6969515B2 (en) Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
ATE111525T1 (de) Plasminogenaktivator-varianten und verfahren zu ihrer herstellung.
KR880007731A (ko) 하이브리드 단백질
FI913909A0 (fi) t-PA pro:n stabilointi
CA2046598C (en) T-pa solubilisation

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid